Open Access

Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease

  • Onofre Combarros1Email author,
  • Cornelia M van Duijn2,
  • Naomi Hammond3,
  • Olivia Belbin4,
  • Alejandro Arias-Vásquez2,
  • Mario Cortina-Borja5,
  • Michael G Lehmann6,
  • Yurii S Aulchenko2,
  • Maaike Schuur2, 7,
  • Heike Kölsch8,
  • Reinhard Heun8, 9,
  • Gordon K Wilcock10, 11,
  • Kristelle Brown4,
  • Patrick G Kehoe11,
  • Rachel Harrison11,
  • Eliecer Coto12,
  • Victoria Alvarez12,
  • Panos Deloukas3,
  • Ignacio Mateo1,
  • Rhian Gwilliam3,
  • Kevin Morgan4,
  • Donald R Warden6,
  • A David Smith6 and
  • Donald J Lehmann6
Journal of Neuroinflammation20096:22

DOI: 10.1186/1742-2094-6-22

Received: 9 July 2009

Accepted: 23 August 2009

Published: 23 August 2009

Abstract

Background

Chronic inflammation is a characteristic of Alzheimer's disease (AD). An interaction associated with the risk of AD has been reported between polymorphisms in the regulatory regions of the genes for the pro-inflammatory cytokine, interleukin-6 (IL-6, gene: IL6), and the anti-inflammatory cytokine, interleukin-10 (IL-10, gene: IL10).

Methods

We examined this interaction in the Epistasis Project, a collaboration of 7 AD research groups, contributing DNA samples from 1,757 cases of AD and 6,295 controls.

Results

We replicated the interaction. For IL6 rs2069837 AA × IL10 rs1800871 CC, the synergy factor (SF) was 1.63 (95% confidence interval: 1.10–2.41, p = 0.01), controlling for centre, age, gender and apolipoprotein E ε4 (APOEε4) genotype. Our results are consistent between North Europe (SF = 1.7, p = 0.03) and North Spain (SF = 2.0, p = 0.09). Further replication may require a meta-analysis. However, association due to linkage disequilibrium with other polymorphisms in the regulatory regions of these genes cannot be excluded.

Conclusion

We suggest that dysregulation of both IL-6 and IL-10 in some elderly people, due in part to genetic variations in the two genes, contributes to the development of AD. Thus, inflammation facilitates the onset of sporadic AD.

Background

Alzheimer's disease (AD) is accompanied by a chronic inflammatory process, including activation of microglia and astrocytes that express pro-inflammatory cytokines [1, 2]. It is unclear to what extent this inflammation is a reaction to the pathology of AD, and to what extent it contributes to the onset or progression of the disease.

Two multi-functional cytokines, interleukin-6 (IL-6) and interleukin-10 (IL-10), may be relevant to this question. IL-6 is a potent pro-inflammatory cytokine [3], while IL-10 acts to limit inflammation in the brain [4]. Both are produced by activated microglia and astrocytes [3, 4]. Two single nucleotide polymorphisms (SNPs), rs1800795 (-174G/C) and rs1800896 (-1082G/A), in the regulatory regions of the genes, IL6 and IL10, respectively, have been widely studied. However, the ongoing AlzGene meta-analyses of the two SNPs [5]http://​www.​alzforum.​org/​res/​com/​gen/​alzgene/​ are both currently negative (4 July 2009): pooled odds ratios for Caucasians in single-locus analyses of IL6-174C versus G alleles = 0.93 (95% confidence interval: 0.79–1.08, 14 studies) and of IL10-1082G versus A alleles = 0.91 (0.74–1.11, eight studies). Our own meta-analyses, both by allele and by genotype, confirmed these results and also indicated a high degree of heterogeneity among the studies (p < 0.05 in seven out of eight analyses, data not shown). Such inconsistencies may be due to study differences, e.g. in design or technical or analytical approach. However, the heterogeneity remained in six out of eight analyses after altogether four studies with controls in Hardy-Weinberg disequilibrium were removed. Alternatively, the heterogeneity may reflect true population differences, such as in interactions with other factors, including other genes. Such diverse results have been described as a marker of epistasis [6, 7], i.e. where the effect of one polymorphism depends on the genotype at another locus.

Infante et al (2004) [8] reported an interaction between IL6-174G/C and IL10-1082G/A associated with the risk of AD. We therefore set out to replicate this result in the Epistasis Project.

The Epistasis Project

Sporadic Alzheimer's disease (AD) is a complex disease, with over 50% heritability [9]. This suggests that its study requires the investigation of interactions between risk factors, particularly genetic factors. The Epistasis Project studies such interactions, mainly those between distinct genetic loci, i.e. epistasis. The project is a collaboration of seven AD research groups: Bonn, Bristol, Nottingham, OPTIMA, Oviedo, Rotterdam and Santander (Table 1). The project aims: first, to replicate genetic interactions that have been reported to affect the risk of sporadic AD; second, to explore other polymorphisms in the relevant genetic regions, ultimately to reveal the true risk loci. The overriding object is to gain insights into AD causality. However, interactions can only be reliably studied with sufficient statistical power and careful study design. The project therefore has these characteristics:-
Table 1

Sample-sets used in the Epistasis Project

Group

Geographical Region*

Subjects

Numbers

% women

p (AD vs controls)

Median age (interquartile range)

p (AD vs controls)

Bonn

Bonn and Mainz, Germany

Clinical AD

259

61.4

 

71.0 (65.1–77.5)

 
  

Screened controls

232

56.9

0.31

67.8 (64.4–76.1)

0.11

Bristol

South-West England

Autopsy AD

200

45.0

 

80.4 (75.6–86.0)

 
  

Autopsy controls

57

40.4

0.55

77.9 (72.8–82.9)

0.12

Nottingham

Cambridge, England

Autopsy AD

104

48.1

 

78.7 (70.8–84.6)

 
  

Autopsy controls

107

34.6

0.051

72.5 (65.6–80.0)

< 0.001

OPTIMA

Oxford, England

Autopsy AD

163

54.6

 

79.5 (72.4–85.2)

 
  

Clinical AD

87

54.0

 

79.1 (73.4–84.8)

 
  

Screened controls

261

53.6

0.93

78.9 (72.9–83.8)

0.54

Oviedo

Asturias, Spain

Clinical AD

202

69.8

 

78.4 (74.8–82.8)

 
  

Screened controls

131

61.8

0.15

69.7 (63.5–74.5)

< 0.001

Rotterdam

Rotterdam (Ommord), the Netherlands

Clinical AD

391

74.9

 

86.6 (82.2–91.6)

 
  

Screened controls

5,111

57.7

< 0.001

76.9 (71.7–83.0)

< 0.001

Santander

Cantabria, Spain

Clinical AD

351

65.0

 

75.5 (70.8–78.9)

 
  

Screened controls

396

68.9

0.27

80.9 (74.7–85.6)

< 0.001

Totals

 

Total AD

1,757

62.4

 

79.0 (73.0–85.2)

 
  

Total controls

6,295

57.7

 

76.9 (71.3–83.0)

 

AD = Alzheimer's disease

*from which the samples were drawn.

Clinical AD cases were diagnosed as "probable AD" by NINCDS-ADRDA criteria [12]; autopsy AD cases were diagnosed as "definite" or "probable" by CERAD criteria [11]; screened controls were free of cognitive impairment; autopsy controls were free of pathology consistent with AD or other dementias; all controls were ≥ 60 years of age.

Age at death or last examination.

1. Power

The project has 1,757 cases of AD and 6,295 elderly controls. These numbers give 99.9% power to detect an SF [10] of 2 between two polymorphisms, each with a minor allele frequency of 20%, when controlling for individual centres (2 below). They give 89.8% power or 48.6% power to detect SFs of 1.5 or 1.25, respectively. Quality control of genotyping reduces the numbers somewhat, depending on the polymorphism.

2. Selection of sample-sets

Only sample-sets drawn from narrow geographical regions with relatively homogeneous, Caucasian populations have been chosen, from seven AD research centres (Table 1 and Additional file 1).

3. Sample characterisation

Cases of AD are either confirmed at autopsy as "definite" or "probable" by CERAD criteria [11], or clinically diagnosed as "probable AD" by NINCDS-ADRDA criteria [12]. Controls are either screened as free of cognitive impairment, or confirmed at autopsy as free of pathology consistent with AD or other dementias.

4. Matching of cases and controls

Only cases and controls drawn from the same region are compared, thus controlling for geographical differences, e.g. between North and South Europe.

5. Candidate interactions

Interactions are studied that have prior evidence of an association with AD and a plausible biological hypothesis. Interactions with age (± 75 years), gender and apolipoprotein E ε4 (APOEε4) genotype are also examined.

6. Analytical methods

Logistic regression and SF [10] analyses are used. All analyses are controlled for age, gender and APOEε4 genotype. All pooled analyses are also controlled for centre. There is thus no question of controls from one centre (e.g., Rotterdam) being compared with AD cases from another region. Controlling for centre also reduces the relative influence of large subgroups, such as Rotterdam controls, in the pooled result. Where pooled analyses yield significant results, the seven individual centres are also examined for associations with AD, for heterogeneity, and for power to detect the interaction.

Table 1 gives the basic characteristics of the seven sample-sets. See Additional file 1 for further information.

To select the interactions for study, a survey of over 100 published claims and suggestions of epistasis in sporadic AD was undertaken [13]. The interactions finally chosen are involved in various networks that are widely considered to contribute to the development of AD: lipid metabolism [14], β-amyloid metabolism [15], oxidative stress [16], inflammation [1], insulin metabolism [17] and homocysteine metabolism [18]. Positive results should therefore deliver insights into the causes of AD.

Methods

Basic information on the 1,757 cases of AD and the 6,295 controls from the seven centres is given above and in Table 1, and fuller details are provided in Additional file 1.

Genotyping for the six centres other than Rotterdam was performed at the Wellcome Trust Sanger Institute, using the iPLEX Gold assay (Sequenom Inc.). Whole genome amplified DNA was used for 82% of samples; genomic DNA was used for the 18% of samples that were not suitable for whole genome amplification. A Sequenom iPLEX, designed for quality control purposes, was used to assess genotype concordance between genomic and whole genome amplified DNA for 168 individuals. Assays for all SNPs were designed using the eXTEND suite and MassARRAY Assay Design software version 3.1 (Sequenom Inc.). Samples were amplified in multiplexed PCR reactions before allele specific extension. Allelic discrimination was obtained by analysis with a MassARRAY Analyzer Compact mass spectrometer. Genotypes were automatically assigned and manually confirmed using MassArray TyperAnalyzer software version 4.0 (Sequenom Inc.). Gender markers were included in all iPLEX assays as a quality control metric for confirmation of plate/sample identity. Genotyping of SNPs rs1800871, rs2069837 and rs3024505 was carried out using the KASPar technology by KBioscience http://​www.​kbioscience.​co.​uk.

Genotyping in the Rotterdam cohort was done on Version 3 Illumina-Infinium-II HumanHap550 SNP array (Illumina, San Diego, USA) and additionally, SNPs were imputed using MACH software http://​www.​sph.​umich.​edu/​csg/​abecasis/​MACH/​ with HapMap CEU Release 22 as a reference [19]. The reliability of imputation was estimated for each imputed SNP with the ratio of expected and observed dosage variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped; 5974 were available with good quality genotyping data; 5502 of these had reliable phenotypes. For the Epistasis Project, 52 genotyped SNPs and 116 imputed SNPs were selected.

We assessed associations with logistic regression models and SF analysis [10], controlling for age, gender, APOEε4 and study centre, using R Version 2.6.1 (R Foundation for Statistical Computing, Vienna, Austria). Heterogeneity between centres was controlled by fitting a fixed effect corresponding to contrasts between the baseline centre and the six other centres (having compared models with fixed- and random-effect terms in centre, goodness of fit was measured using Akaike's Information Criterion, which favoured using fixed effects only). Where the overall SF was significant at p < 0.05, the seven individual centres and the two geographical regions, North Europe and North Spain, were also examined. Power calculations were by SF analysis. Meta-analyses were performed using the random-effect method of DerSimonian and Laird [20] and the heterogeneity test of Armitage [21]. Comparisons of allelic frequencies between North Spain and North Europe were by Fisher's exact test. We compared the medians of the age distributions of AD and control groups using the Wilcoxon-Mann-Whitney test. Linkage disequilibrium data were estimated using the R genetics library http://​cran.​r-project.​org/​web/​packages/​genetics/​index.​html. All tests of significance were two-sided.

Results

We replicated the interaction reported by Infante et al (2004) [8] between IL6 rs1800795 (-174G/C) and IL10 rs1800896 (-1082G/A) (below). In the Rotterdam cohort, we examined altogether five IL6-related SNPs, rs1800797, rs1800795, rs2069837, rs2069840 and rs2069845, and four IL10-related SNPs, rs1800896, rs1800871, rs3024498 and rs3024505. In that preliminary study, we found that the strongest interactions were seen between IL6 rs2069837 (intron 2 A/G) and IL10 rs1800871 (-819C/T) and between IL6 rs2069837 and IL10 rs3024505 (3' C/T) (data not shown). We therefore studied the five SNPs shown in Table 2 in all seven sample-sets.
Table 2

Studied SNPs

Gene

SNP

 

Minor allele frequency in controls

LD in controls

   

North

Europe

North

Spain

Difference

(p)

With

D'

r2

IL6

rs1800795

-174G/C

41.1% (C)

32.8% (C)

< 0.0001

rs2069837

0.998

0.055

 

rs2069837

Intron 2 A/G

7.3% (G)

9.3% (G)

0.03

   

IL10

rs1800896

-1082G/A

50.7% (G)

43.1% (G)

< 0.0001

rs1800871

0.999

0.296

      

rs3024505

0.988

0.191

 

rs1800871

-819C/T

22.5% (T)

26.7% (T)

0.002

rs3024505

0.999

0.058

 

rs3024505

3' C/T

16.6% (T)

14.2% (T)

0.06

   

SNP = single nucleotide polymorphism; LD = linkage disequilibrium; D' = ratio of observed LD to maximum possible LD; r = correlation coefficient; IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively.

Hardy-Weinberg analysis was performed for the five SNPs of Table 2 in both cases and controls of the Rotterdam samples, genotyped by Rotterdam, and of the samples from the other six centres, genotyped by the Sanger Institute. As expected by chance, one of these 20 analyses resulted in disequilibrium: IL6-174G/C in AD cases of the six centres (p = 0.02). The two IL6 SNPs were in linkage disequilibrium (LD), as were the three IL10 SNPs (Table 2). The allelic frequencies differed significantly between North Europe (Bonn, Bristol, Nottingham, OPTIMA and Rotterdam) and North Spain (Oviedo and Santander) in four out of the five SNPs (Table 2).

We examined the potential associations with AD of the six interactions generated between the two IL6 SNPs and the three IL10 SNPs in our overall dataset (Table 3), controlling for centre, age, gender and APOEε4 genotype (as in all association analyses). Three of the six interactions were associated with AD: SF p < 0.05. The first interaction shown in Table 3 is effectively identical to that reported by Infante et al 2004 [8]; we have merely reversed the first genotype, i.e. CC rather than GC + GG, to give an SF of 1.56, rather than its inverse, 0.64, for easier comparison with the other interactions. The two IL6 genotypes shown in Table 3 were in LD (p < 0.0001), as were the three IL10 genotypes (p < 0.0001). The interaction between IL6 intron 2 AA and IL10-819CC was slightly the strongest: SF = 1.63 (95% confidence interval = 1.10–2.41, p = 0.01). All further analysis was therefore restricted to that interaction.
Table 3

Potential interactions between IL6 SNPs and IL10 SNPs in the risk of AD

Interaction

 

Numbers

 

Adjusted*

synergy factor(95% CI, p)

IL6

× IL10

Controls

AD cases

 

rs1800795 CC

× rs1800896 G+

6153

1557

1.56 (1.02–2.38, 0.04)

rs1800795 CC

× rs1800871 CC

6158

1514

1.25 (0.86–1.80, 0.25)

rs1800795 CC

× rs3024505 T+

6190

1546

1.11 (0.75–1.64, 0.60)

rs2069837 AA

× rs1800896 G+

6126

1437

1.37 (0.89–2.11, 0.16)

rs2069837 AA

× rs1800871 CC

6150

1442

1.63 (1.10–2.41, 0.01)

rs2069837 AA

× rs3024505 T+

6172

1429

1.55 (1.02–2.36, 0.04)

IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; SNPs = single nucleotide polymorphisms; AD = Alzheimer's disease; CI = confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; APOEε4 = apolipoprotein E ε4.

*All analyses controlled for centre, age, gender and APOEε4 genotype.

Table 4 shows the effect of each of the two factors in that interaction on the association with AD of the other factor. The presence of IL10-819CC changed the association of IL6 intron 2 AA with AD from negative (odds ratio = 0.86, p = 0.30) to risk (odds ratio = 1.38, p = 0.02), while the presence of the latter removed the protective association of the former (odds ratio = 0.63, p = 0.01, changed to 1.08, p = 0.32).
Table 4

Odds ratios of Alzheimer's disease for two IL6 and IL10 SNPs, stratified by each other

Odds ratio of AD for :-

In the subset :-

Numbers

 

Adjusted* odds ratio of AD (95% CI, p)

  

Controls

AD cases

 

IL6

IL10

AA: 2158

AA: 518

0.86 (0.64–1.15, 0.30)

rs2069837

rs1800871 T+

G+: 348

G+: 87

 

AA vs G+

IL10

AA: 3099

AA: 724

1.38 (1.06–1.79, 0.02)

 

rs1800871 CC

G+: 545

G+: 113

 

IL10

IL6

CC: 545

CC: 113

0.63 (0.44–0.91, 0.01)

rs1800871

rs2069837 G+

T+: 348

T+: 87

 

CC vs T+

IL6

CC: 3099

CC: 724

1.08 (0.93–1.25, 0.32)

 

rs2069837 AA

T+: 2158

T+: 518

 

IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; AD = Alzheimer's disease; CI = confidence interval; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; APOEε4 = apolipoprotein E ε4.

*All analyses controlled for centre, age, gender and APOEε4 genotype.

There was significant heterogeneity between the centres, and the interaction was only significant in one of the seven centres, Rotterdam, with an SF of 3.0 (95% confidence interval = 1.6–5.8, p = 0.0007). But the power to detect an SF of 1.6 was low in each centre, ranging from below 10% to 40%. The results for North Europe (SF = 1.7, p = 0.03) and for North Spain (SF = 2.0, p = 0.09) were consistent (Table 5).
Table 5

Interaction between IL6 rs2069837 AA vs G+ and IL10 rs1800871 CC vs T+, by region

Region

Power*

Adjusted synergy factor (95% CI, p) in the risk of AD

North Europe

64%

1.7 (1.05–2.6, 0.03)

North Spain

37%

2.0 (0.9–4.4, 0.09)

All

76%

1.6 (1.1–2.4, 0.01)

IL6 and IL10 = the genes for interleukin-6 and interleukin-10, respectively; G+ and T+ group the genotypes, GA+GG and CT+TT, respectively; CI = confidence interval; AD = Alzheimer's disease; APOEε4 = apolipoprotein E ε4.

*To detect a synergy factor of 1.6 (as in the overall dataset) at 0.05.

All analyses controlled for centre, age, gender and APOEε4 genotype.

North Europe = Rotterdam, Bonn, OPTIMA, Nottingham and Bristol; North Spain = Santander and Oviedo.

Results were similar for men as for women (data not shown). The interaction was slightly stronger in older subjects: SF for > 75 years = 1.71 (1.05–2.78, 0.03); SF for < 75 years = 1.27 (0.56–2.87, 0.57). However, there was no 3-way interaction with age. Nor did we find a significant interaction with APOEε4.

Discussion

In our whole dataset of over 7,500 samples, we have replicated both the interaction reported by Infante et al 2004 [8] and also that found in our preliminary study in the Rotterdam dataset, between SNPs of IL6 and IL10 (Table 3). Both interactions gave significant SFs of approximately 1.6. There was significant heterogeneity between centres, which was unsurprising since only two, Rotterdam and Santander, had > 20% power to detect these interactions. But the results for the two main regions, North Europe and North Spain, were consistent (Table 5). We conclude that this is likely to be a true effect, but not a very strong one. As in any example of true epistasis, the presence or absence of one factor critically influenced the effect of the other (Table 4).

Further replication will require a dataset at least as large, with appropriate statistical control for differences between individual sample-sets. Underpowered studies are unhelpful, since chance can produce misleading results in such cases. This criticism may apply to a previous study of this interaction that had power of < 2% to detect it. Even the large Rotterdam Study, with 395 cases of AD and 5,111 controls, only had 40% power to detect this interaction. Thus, further replication may require a meta-analysis.

IL-6 in age-related decline and in AD

There is much evidence that chronic, low-grade overexpression of IL-6 contributes to age-related decline. Blood levels of IL-6 can rise with age in humans [2224]. Raised levels are associated with various age-related conditions, including risk of cognitive decline in some studies [25, 26], but not in all [27]. Raised levels have been consistently associated with increased mortality in several large prospective studies [2831]. Raised levels have also been associated with various conditions considered to be risk factors for dementia and/or AD: subclinical and clinical cardiovascular disease and the risk thereof [3234], type 2 diabetes and its risk [35, 36], psychological stress [37] and the damage following stroke (IL-6 also increased in CSF) [38, 39].

Further, raised blood levels of IL-6 have often been associated with AD [4042] and also with the risk of AD [43], although not in all studies [44, 45]. Post-mortem studies, although small, have generally reported increased IL-6 levels or changed IL-6 distribution in AD brain [4649], with one exception [50]. IL-6 was found not only in plaques, but also around the bodies of isocortical neurones, only in AD [46]. This evidence and that above suggest that dysregulation of IL-6 contributes to the development of AD.

A potential interaction between IL6 and IL10

Both IL-6 and IL-10 are produced by activated microglia and astrocytes (reviewed in [3, 4]). However, in contrast to IL-6, IL-10 acts to limit inflammation in the brain. IL-10 inhibits the production of IL-6 [51, 52] and its receptor [53]. Thus, certain combinations of genetic variants of IL6 and IL10, i.e. those associated with high production of IL-6 combined with those associated with low production of IL-10, may contribute to the dysregulation of inflammation. High heritability (> 50%) has been reported for in vitro stimulated production of both IL-6 and IL-10 [54]. The functions of two of our studied SNPs, IL6 intron 2 A/G and IL10 3' C/T have not yet been investigated. Thus we cannot rule out that they might have effects on transcription or post-transcriptional processing. Alternatively, they may be in linkage disequilibrium with other, functional variants. On the other hand, studies of IL6-174G/C [55, 56], of IL10-819C/T [57] and of IL10-1082G/A [5860] have reported that these SNPs affect transcription or are in linkage disequilibrium with those that do. However, it may be premature to designate any particular alleles as high or low producers, since there have been contrasting results for the effects of IL6-174G/C and IL10-1082G/A on transcription, on in vitro stimulated production and on blood levels of the respective proteins. But most studies have associated the IL10-1082GG genotype at least with higher in vitro stimulated production of IL-10 [6164], although not all, [65, 66] and results have varied with experimental conditions [64, 66]. It appears that several SNPs in the regulatory regions of each gene affect transcription in an interactive and tissue-specific manner [56]. Indeed, we note that in our dataset the 2-SNP combination of IL10 -1082G+/-819CC has a slightly stronger interaction with IL6 than that of either SNP alone (data not shown).

Conclusion

We conclude that an interaction between IL-6 and IL-10 is plausible; that dysregulation of the two genes contributes to chronic low-grade inflammation in some elderly people and thus to the risk of AD; and that certain combinations of genetic variants in the regulatory regions of the two genes are conducive to this dysregulation. But in view of the linkage disequilibrium in the region of each gene (Table 2), we cannot conclude that we have yet found the true risk polymorphisms. However, we suggest that our results are consistent with the contribution of inflammation to the onset of AD.

Abbreviations

AD: 

Alzheimer's disease

APOEε4: 

apolipoprotein E ε4

CERAD: 

Consortium to Establish a Registry for Alzheimer's Disease

CSF: 

cerebrospinal fluid

IL-6: 

interleukin-6

IL6

the gene for interleukin-6

IL-10: 

interleukin-10

IL10

the gene for interleukin-10

NINCDS-ADRDA: 

National Institute of Neurological, Communicative Diseases and Stroke-Alzheimer's Disease and Related Diseases Association

OPTIMA: 

the Oxford Project to Investigate Memory and Ageing

SF

synergy factor

SNP: 

single nucleotide polymorphism.

Declarations

Acknowledgements

We are most grateful to the Moulton Charitable Foundation for a grant to fund the Epistasis Project and to all those who have provided support for the individual clinical studies. GW was partly supported by the NIHR Biomedical Research Centre, Oxford. UCL Institute of Child Health receives funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. The Centre for Paediatric Epidemiology and Biostatistics also benefits from funding support from the Medical Research Council in its capacity as the MRC Centre of Epidemiology for Child Health (G0400546).

Authors’ Affiliations

(1)
Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Marqués de Valdecilla University Hospital (University of Cantabria)
(2)
Department of Epidemiology, Erasmus MC University Medical Center
(3)
The Wellcome Trust Sanger Institute
(4)
School of Molecular Medical Sciences, Institute of Genetics, University of Nottingham, Queens Medical Centre
(5)
Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London
(6)
Oxford Project to Investigate Memory and Ageing (OPTIMA), University Department of Physiology, Anatomy and Genetics
(7)
Department of Neurology, Erasmus MC University Medical Center
(8)
Department of Psychiatry, University of Bonn
(9)
Department of Psychiatry, Derby City General Hospital
(10)
Nuffield Department of Medicine, University of Oxford, Level 4, John Radcliffe Hospital
(11)
Dementia Research Group, Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital
(12)
Genética Molecular, Hospital Central de Asturias

References

  1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al: Inflammation and Alzheimer's disease. Neurobiol Aging. 2000, 21: 383-421. 10.1016/S0197-4580(00)00124-X.PubMed CentralView ArticlePubMed
  2. Rogers J, Webster S, Lue L-F, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P: Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging. 1996, 17: 681-686. 10.1016/0197-4580(96)00115-7.View ArticlePubMed
  3. Gruol DL, Nelson TE: Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol. 1997, 15: 307-339. 10.1007/BF02740665.View ArticlePubMed
  4. Strle K, Zhou JH, Shen W-H, Broussard SR, Johnson RW, Freund GG, Dantzer R, Kelley KW: Interleukin-10 in the brain. Crit Rev Immunol. 2001, 21: 427-449.View ArticlePubMed
  5. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE: Systematic meta-analyses of Alzheimer disease genetic association studies: the Alzgene database. Nature Genetics. 2007, 39: 17-23. 10.1038/ng1934. Accessed on 14 July, 2009.View ArticlePubMed
  6. Moore JH, Williams SM: Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. BioEssays. 2005, 27: 637-646. 10.1002/bies.20236.View ArticlePubMed
  7. Wade MJ: Epistasis, complex traits, and mapping genes. Genetica. 2001, 112–113: 59-69. 10.1023/A:1013316611768.View ArticlePubMed
  8. Infante J, Sanz C, Fernández-Luna JL, Llorca J, Berciano J, Combarros O: Gene-gene interaction between interleukin-6 and interleukin-10 reduces AD risk. Neurology. 2004, 63: 1135-1136.View ArticlePubMed
  9. Bergem ALM, Engedal K, Kringlen E: The role of heredity in late-onset Alzheimer disease and vascular dementia – a twin study. Arch Gen Psychiatry. 1997, 54 (3): 264-270.View ArticlePubMed
  10. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ: The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes. 2009, 2 (1): 105-10.1186/1756-0500-2-105.PubMed CentralView ArticlePubMed
  11. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991, 41: 479-486.View ArticlePubMed
  12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology. 1984, 34: 939-944.View ArticlePubMed
  13. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ: Epistasis in sporadic Alzheimer's disease. Neurobiol Aging. 2009, 30: 1333-1349. 10.1016/j.neurobiolaging.2007.11.027.View ArticlePubMed
  14. Carter CJ: Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int. 2007, 50: 12-38. 10.1016/j.neuint.2006.07.007.View ArticlePubMed
  15. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126/science.1072994.View ArticlePubMed
  16. Perry G, Nunomura A, Hirai K, Zhu X, Pérez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM, et al: Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Rad Biol Med. 2002, 33: 1475-1479. 10.1016/S0891-5849(02)01113-9.View ArticlePubMed
  17. Craft S: The role of metabolic disorders in Alzheimer disease and vascular dementia. Arch Neurol. 2009, 66: 300-305. 10.1001/archneurol.2009.27.PubMed CentralPubMed
  18. Smith AD: The worldwide challenge of the dementias: a role for B vitamins and homocysteine?. Food Nutr Bull. 2008, 29: S143-S172.View ArticlePubMed
  19. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, Debette S, Lumley T, Folsom AR, van den Herik EG, et al: Genomewide association studies of stroke. N Engl J Med. 2009, 360: 1718-1728. 10.1056/NEJMoa0900094.PubMed CentralView ArticlePubMed
  20. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.View ArticlePubMed
  21. Armitage P: Statistical Methods in Medical Research. 1983, Oxford: Blackwell Scientific Publications
  22. Ershler WB: Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc. 1993, 41: 176-181.View ArticlePubMed
  23. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J: Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging. 1994, 15: 771-772. 10.1016/0197-4580(94)90066-3.View ArticlePubMed
  24. Young DG, Skibinski G, Mason JI, James K: The influence of age and gender on serum dehydroepiandrosterone sulphate (DHEA-S), IL-6, IL-6 soluble receptor (IL-6 sR) and transforming growth factor β1 (TGF-β1) levels in normal healthy blood donors. Clin Exp Immunol. 1999, 117: 476-481. 10.1046/j.1365-2249.1999.01003.x.PubMed CentralView ArticlePubMed
  25. Weaver JD, Huang M-H, Albert M, Harris T, Rowe JW, Seeman TE: Interleukin-6 and risk of cognitive decline. Neurology. 2002, 59: 371-378.View ArticlePubMed
  26. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T: Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003, 61: 76-80.View ArticlePubMed
  27. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P: Serum inflammatory proteins and cognitive decline in older persons. Neurology. 2005, 64: 1371-1377.View ArticlePubMed
  28. Cohen HJ, Harris T, Peiper CF: Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003, 114: 180-187. 10.1016/S0002-9343(02)01484-5.View ArticlePubMed
  29. Harris TB, Ferrucci L, Tracy RP, Corti M-C, Wacholder S, Ettinger WHJ, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999, 106: 506-512. 10.1016/S0002-9343(99)00066-2.View ArticlePubMed
  30. Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP, Seeman TE: Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc. 2002, 50: 638-644. 10.1046/j.1532-5415.2002.50157.x.View ArticlePubMed
  31. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women's Health and Aging Study. Circulation. 2001, 103: 947-953.View ArticlePubMed
  32. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, et al: Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003, 108: 2317-2322. 10.1161/01.CIR.0000097109.90783.FC.View ArticlePubMed
  33. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Tracy RP, Rubin SM, Harris TB, Pahor M: Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] study). Am J Cardiol. 2003, 92: 522-528. 10.1016/S0002-9149(03)00718-5.View ArticlePubMed
  34. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000, 101: 1767-1772.View ArticlePubMed
  35. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001, 286: 327-334. 10.1001/jama.286.3.327.View ArticlePubMed
  36. Testa R, Olivieri F, Bonfigli AR, Sirolla C, Boemi M, Marchegiani F, Marra M, Cenerelli S, Antonicelli R, Dolci A, et al: Interleukin-6-174G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2006, 71: 299-305. 10.1016/j.diabres.2005.07.007.View ArticlePubMed
  37. Kiecolt-Glaser JK, Preacher KJ, MacCullum RC, Atkinson C, Malarkey WB, Glaser R: Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA. 2003, 100: 9090-9095. 10.1073/pnas.1531903100.PubMed CentralView ArticlePubMed
  38. Castellanos M, Castillo J, García MM, Leira R, Serena J, Chamorro A, Dávalos A: Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke. 2002, 33: 982-987. 10.1161/hs0402.105339.View ArticlePubMed
  39. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, Tarkowski A: Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 1995, 26: 1393-1398.View ArticlePubMed
  40. Baranowska-Bik A, Bik W, Wolinska-Witort E, Martynska L, Chmielowska M, Barcikowska M, Baranowska B: Plasma β amyloid and cytokine profile in women with Alzheimer's disease. Neuro Endocrinol Lett. 2008, 29: 75-79.PubMed
  41. Bermejo P, Martín-Aragón S, Benedí J, Susín C, Felici E, Gil P, Ribera JM, Villar ÁM: Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett. 2008, 117: 198-202. 10.1016/j.imlet.2008.02.002.View ArticlePubMed
  42. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LME: Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J Neuroimmunol. 2000, 103: 97-102. 10.1016/S0165-5728(99)00226-X.View ArticlePubMed
  43. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM: Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol. 2004, 61: 668-672. 10.1001/archneur.61.5.668.View ArticlePubMed
  44. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, Mariani E, Licastro F, Patterson C: Blood inflammatory markers and risk of dementia: the Conselice Study of Brain Aging. Neurobiol Aging. 2007, 28: 1810-1820. 10.1016/j.neurobiolaging.2006.08.012.View ArticlePubMed
  45. van Duijn CM, Hofman A, Nagelkerken L: Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci Lett. 1990, 108: 350-354. 10.1016/0304-3940(90)90666-W.View ArticlePubMed
  46. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, Yolk B, Berger M: Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 1991, 285: 111-114. 10.1016/0014-5793(91)80737-N.View ArticlePubMed
  47. Hampel H, Haslinger A, Scheloske M, Padberg F, Fischer P, Unger J, Teipel SJ, Neumann M, Rosenberg C, Oshida R, et al: Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. Eur Arch Psychiatry Clin Neurosci. 2005, 255: 269-278. 10.1007/s00406-004-0558-2.View ArticlePubMed
  48. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM: Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 2000, 57: 1153-1160. 10.1001/archneur.57.8.1153.View ArticlePubMed
  49. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, Quirion R: Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 1993, 629: 245-252. 10.1016/0006-8993(93)91327-O.View ArticlePubMed
  50. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD: Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord. 1998, 12: 215-227. 10.1097/00002093-199809000-00016.View ArticlePubMed
  51. Heyen JR, Ye S, Finck BN, Johnson RW: Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NFκ B. Brain Res Mol Brain Res. 2000, 77: 138-147. 10.1016/S0169-328X(00)00042-5.View ArticlePubMed
  52. Szczepanik AM, Funes S, Petko W, Ringheim GE: IL-4, IL-10 and IL-13 modulate Aβ (1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol. 2001, 113: 49-62. 10.1016/S0165-5728(00)00404-5.View ArticlePubMed
  53. Sawada M, Suzumura A, Hosoya H, Marunouchi T, Nagatsu T: Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J Neurochem. 1999, 72: 1466-1471. 10.1046/j.1471-4159.1999.721466.x.View ArticlePubMed
  54. Posthuma D, Meulenbelt I, de Craen AJM, de Geus EJC, Slagboom PE, Boomsma DI, Westendorp RGJ: Human cytokine response to ex vivo amyloid-β stimulation is mediated by genetic factors. Twin Res Hum Genet. 2005, 8: 132-137.View ArticlePubMed
  55. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998, 102: 1369-1376. 10.1172/JCI2629.PubMed CentralView ArticlePubMed
  56. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000, 275: 18138-18144. 10.1074/jbc.M000379200.View ArticlePubMed
  57. Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz C: Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut. 2004, 53 (8): 1082-1089. 10.1136/gut.2003.029736.PubMed CentralView ArticlePubMed
  58. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P: Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999, 42: 1101-1108. 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y.View ArticlePubMed
  59. Rees LE, Wood NA, Gillespie KM, Lai KN, Gaston K, Mathieson PW: The interleukin-10 -1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci. 2002, 59: 560-569. 10.1007/s00018-002-8448-0.View ArticlePubMed
  60. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T: Differential regulation of interleukin-10 production by genetic and environmental factors – a twin study. Genes Immun. 2002, 3: 407-413. 10.1038/sj.gene.6363920.View ArticlePubMed
  61. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP: Cytokine (TNFα, LT α l and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun. 2000, 1: 185-190. 10.1038/sj.gene.6363657.View ArticlePubMed
  62. Suárez A, Castro P, Alonso R, Mozo L, Gutiérrez C: Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation. 2003, 75: 711-717. 10.1097/01.TP.0000055216.19866.9A.View ArticlePubMed
  63. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997, 24: 1-8.View ArticlePubMed
  64. Yilmaz V, Yentür SP, Saruhan-Direskeneli G: IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine. 2005, 30: 188-194. 10.1016/j.cyto.2005.01.006.View ArticlePubMed
  65. Huizinga TWJ, Keijsers V, Yanni G, Hall M, Ramage W, Lanchbury J, Pitzalis C, Drossaers-Bakker WK, Westendorp RGJ, Breedveld FC, et al: Are differences in interleukin 10 production associated with joint damage?. Rheumatology. 2000, 39: 1180-1188. 10.1093/rheumatology/39.11.1180.View ArticlePubMed
  66. Warlé MC, Farhan A, Metselaar HJ, Hop WCJ, Perrey C, Zondervan PE, Kap M, Kwekkeboom J, Ijzermans JNM, Tilanus HW, et al: Are cytokine gene polymorphisms related to in vitro cytokine production profiles?. Liver Transpl. 2003, 9: 170-181. 10.1053/jlts.2002.50014.View ArticlePubMed

Copyright

© Combarros et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement